title: Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
abstract: NY-ESO-1 specific humoral responses are frequently observed in patients with various types of NY-ESO-1 antigen expressing tumors. In a large proportion of NY-ESO-1 antibody-positive patients of NY-ESO-1-specific CD8 T-cells can also be detected suggesting that monitoring of the NY-ESO-1 specific humoral immune response may be a relevant and more practical surrogate for estimating the overall immune response against NY-ESO-1 in clinical vaccine studies. We have immunized 9 cancer patients with full length NY-ESO-1 protein formulated with cholesterol-bearing hydrophobized pullulan (CHP-NY-ESO-1) and investigated the humoral immune responses against NY-ESO-1. Seven patients were NY-ESO-1 antibody-negative and 2 patients were positive prior to vaccination. Vaccination with CHP-NY-ESO-1 resulted in the induction or increase of NY-ESO-1 antibody responses in all 9 patients immunized. Epitope analysis revealed 5 regions in the NY-ESO-1 protein molecule that were recognized by antibodies induced after vaccination. The 5 regions were also recognized by antibodies present in nonvaccinated, NY-ESO-1 antibody-positive cancer patients. A peptide spanning amino acids 91-108 was recognized in 6 out of 9 vaccinated patients and in 8 out of 9 nonvaccinated, sero-positive patients, being the most dominant antigenic epitope in NY-ESO-1 for antibody recognition in cancer patients. In conclusion, we showed that CHP-NY-ESO-1 protein vaccination had a potent activity for inducing humoral immune responses against NY-ESO-1 antigen in cancer patients. The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1.
authors.affiliation: Department of Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan.
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kawabata
authors.forename: Hisashi
authors.initials: H
authors.lastname: Wada
authors.forename: Midori
authors.initials: M
authors.lastname: Isobe
authors.forename: Takashi
authors.initials: T
authors.lastname: Saika
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Sato
authors.forename: Akiko
authors.initials: A
authors.lastname: Uenaka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Miyata
authors.forename: Takushi
authors.initials: T
authors.lastname: Yasuda
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Doki
authors.forename: Yuji
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Tsuji
authors.forename: Keiji
authors.initials: K
authors.lastname: Iwatsuki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Shiku
authors.forename: Gerd
authors.initials: G
authors.lastname: Ritter
authors.forename: Roger
authors.initials: R
authors.lastname: Murphy
authors.forename: Eric
authors.initials: E
authors.lastname: Hoffman
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
authors.forename: Eiichi
authors.initials: E
authors.lastname: Nakayama
mesh_terms: D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000276:immunology; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002784:Cholesterol / Q000008:administration & dosage* / Q000276:immunology; D018604:Epitope Mapping / Q000379:methods; D005936:Glucans / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000276:immunology; D008565:Membrane Proteins / Q000008:administration & dosage / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D014611:Vaccination / Q000379:methods*
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D019496:Cancer Vaccines; D005936:Glucans; D007074:Immunoglobulin G; D008565:Membrane Proteins; C009109:pullulan; D002784:Cholesterol